Jean-Marc Sabatier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6721633/publications.pdf

Version: 2024-02-01

94269 128067 4,665 149 37 60 citations h-index g-index papers 161 161 161 4356 docs citations citing authors all docs times ranked

#	Article	IF	CITATIONS
1	Top-down and Bottom-up Approaches Revealed New Categories of Peptides from the Venom of Moroccan Scorpion <i>Androctonus mauretanicus</i> . Venoms and Toxins, 2022, 2, .	0.3	1
2	Current Treatments and Therapeutic Options for COVID-19 Patients: A Systematic Review. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	27
3	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	23
4	COVID-19 in Pediatrics: A Systematic Review of Current Knowledge and Practice. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	20
5	Toxins and Venoms from Marine Cnidarians and Gastropods: Diversity and Potential Drugs Targeting the Ion Channels. Venoms and Toxins, 2022, 2, .	0.3	O
6	Parkinson disease: Protective role and function of neuropeptides. Peptides, 2022, 151, 170713.	1.2	6
7	Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases. Molecules, 2022, 27, 2048.	1.7	38
8	Discovery of Leptulipin, a New Anticancer Protein from theIranian Scorpion, Hemiscorpius lepturus. Molecules, 2022, 27, 2056.	1.7	5
9	SARS-CoV-2-Induced Neurological Disorders in Symptomatic Covid-19 and Long Covid Patients: Key Role of Brain Renin-Angiotensin System. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	11
10	The relationship between COVID $\hat{a}\in19$ viral load and disease severity: A systematic review. Immunity, Inflammation and Disease, 2022, 10, .	1.3	86
11	The Pathophysiology of Long COVID throughout the Renin-Angiotensin System. Molecules, 2022, 27, 2903.	1.7	44
12	Neuro- and Cardiovascular Activities of Montivipera bornmuelleri Snake Venom. Biology, 2022, 11, 888.	1.3	4
13	Structural Dynamics of the SARS-CoV-2 Spike Protein: A 2-Year Retrospective Analysis of SARS-CoV-2 Variants (from Alpha to Omicron) Reveals an Early Divergence between Conserved and Variable Epitopes. Molecules, 2022, 27, 3851.	1.7	12
14	Fast killing kinetics, significant therapeutic index, and high stability of melittin-derived antimicrobial peptide. Amino Acids, 2022, 54, 1275-1285.	1.2	7
15	Separation and Analytical Techniques Used in Snake Venomics: A Review Article. Processes, 2022, 10, 1380.	1.3	4
16	Bee Venom PLA2 Versus Snake Venom PLA2: Evaluation of Structural and Functional Properties. Venoms and Toxins, 2021, 01, .	0.3	5
17	Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. International Journal of Biological Sciences, 2021, 17, 2348-2355.	2.6	31
18	La nigelle et le mielÂ: un traitement efficace anti-COVID-19Â?. HEGEL - HEpato-GastroEntérologie Libérale, 2021, N° 1, 51-56.	0.0	1

#	Article	IF	CITATIONS
19	The Cytotoxic Effect of Apis mellifera Venom with a Synergistic Potential of Its Two Main Components—Melittin and PLA2—On Colon Cancer HCT116 Cell Lines. Molecules, 2021, 26, 2264.	1.7	23
20	Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers. Molecules, 2021, 26, 2266.	1.7	16
21	Snake Venom Components: Tools and Cures to Target Cardiovascular Diseases. Molecules, 2021, 26, 2223.	1.7	21
22	Discovery of a New Analgesic Peptide, Leptucin, from the Iranian Scorpion, Hemiscorpius lepturus. Molecules, 2021, 26, 2580.	1.7	13
23	Editorial: Venoms, Animal and Microbial Toxins. Frontiers in Pharmacology, 2021, 12, 706573.	1.6	0
24	Genetic susceptibility of COVID-19: a systematic review of current evidence. European Journal of Medical Research, 2021, 26, 46.	0.9	57
25	Mass spectrometryâ€based topâ€down and bottomâ€up approaches for proteomic analysis of the Moroccan <i>Buthus occitanus</i> scorpion venom. FEBS Open Bio, 2021, 11, 1867-1892.	1.0	9
26	First Detection of Tobacco Mosaic Virus in Tobacco Fields in Northern Lebanon. Infectious Disorders - Drug Targets, 2021, 21, 534-540.	0.4	1
27	Beehive Products as Antibacterial Agents: A Review. Antibiotics, 2021, 10, 717.	1.5	24
28	Shared Food, Meals and Drinks: 10 Arguments Suggesting an Oral Transmission Route of SARS-CoV-2. Infectious Disorders - Drug Targets, 2021, 21, .	0.4	1
29	Montivipera bornmuelleri Venom: Inhibitory Effect on Staphylococcus epidermidis and Escherichia coli F1F0-ATPases and Cytotoxicity on HCT116 Cancer Cell Lines. Sci, 2021, 3, 31.	1.8	0
30	Dairy-Derived and Egg White Proteins in Enhancing Immune System Against COVID-19. Frontiers in Nutrition, 2021, 8, 629440.	1.6	11
31	DAMPening Severe COVID-19 with Dexamethasone. Infectious Disorders - Drug Targets, 2021, 21, .	0.4	5
32	Antimicrobial Peptides: A Potent Alternative to Antibiotics. Antibiotics, 2021, 10, 1095.	1.5	125
33	Counter-Regulatory Renin-Angiotensin System: An Important Line of Research to Understand and Limit the Severity of COVID-19. Infectious Disorders - Drug Targets, 2021, 21, .	0.4	9
34	Voltage-Gated Sodium Channels: A Prominent Target of Marine Toxins. Marine Drugs, 2021, 19, 562.	2.2	12
35	The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19. Molecules, 2021, 26, 6945.	1.7	41
36	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. Molecules, 2020, 25, 119.	1.7	8

#	Article	IF	CITATIONS
37	Vitamin D and survival in COVID-19 patients: A quasi-experimental study. Journal of Steroid Biochemistry and Molecular Biology, 2020, 204, 105771.	1.2	172
38	Potential Inhibitory Effect of Apis mellifera's Venom and of Its Two Main Components—Melittin and PLA2—on Escherichia coli F1F0-ATPase. Antibiotics, 2020, 9, 824.	1.5	7
39	Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence. Frontiers in Pharmacology, 2020, 11, 1344.	1.6	32
40	Counter-regulatory â€~Renin-Angiotensin' System-based Candidate Drugs to Treat COVID-19 Diseases in SARS-CoV-2-infected Patients. Infectious Disorders - Drug Targets, 2020, 20, 407-408.	0.4	49
41	SARS-CoV-2 & Samp; Covid-19: Key-Roles of the  Renin-Angiotensin' System / Vitamin D Impacting Drug and Vaccine Developments. Infectious Disorders - Drug Targets, 2020, 20, 348-349.	0.4	31
42	Isolation, Characterization and Chemical Synthesis of Large Spectrum Antimicrobial Cyclic Dipeptide (I-leu-l-pro) from Streptomyces misionensis V16R3Y1 Bacteria Extracts. A Novel 1H NMR Metabolomic Approach. Antibiotics, 2020, 9, 270.	1.5	24
43	Point of view: Should COVID-19 patients be supplemented with vitamin D?. Maturitas, 2020, 140, 24-26.	1.0	33
44	Topology, Antiviral Functional Residues and Mechanism of IFITM1. Viruses, 2020, 12, 295.	1.5	12
45	Antibacterial Peptides. Antibiotics, 2020, 9, 142.	1.5	3
46	Neurological, Cognitive, and Behavioral Disorders during <scp>COVID</scp> â€19: The Nitric Oxide Track. Journal of the American Geriatrics Society, 2020, 68, 1922-1923.	1.3	9
47	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7. Molecules, 2020, 25, 2968.	1.7	5
48	Novel Mutant Phospholipase D from Hemiscorpius lepturus Acts as A Highly Immunogen in BALB/c Mice Against the Lethality of Scorpion Venom. Molecules, 2020, 25, 1673.	1.7	4
49	A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1233-1239.	2.5	25
50	Antimicrobials from Venomous Animals: An Overview. Molecules, 2020, 25, 2402.	1.7	51
51	Reinfection risk of novel coronavirus (CoVID-19): A systematic ‎review of current evidence. World Journal of Virology, 2020, 9, 79-90.	1.3	69
52	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–5. Molecules, 2019, 24, 2415.	1.7	5
53	Venoms of Iranian Scorpions (Arachnida, Scorpiones) and Their Potential for Drug Discovery. Molecules, 2019, 24, 2670.	1.7	12
54	Development of a human scFv antibody targeting the lethal Iranian cobra (Naja oxiana) snake venom. Toxicon, 2019, 171, 78-85.	0.8	10

#	Article	IF	CITATIONS
55	Bee Venom: Overview of Main Compounds and Bioactivities for Therapeutic Interests. Molecules, 2019, 24, 2997.	1.7	175
56	Proteomics study of Southern Punjab Pakistani cobra (<i>Naja naja</i> : formerly <i>Naja naja) Tj ETQq0 0 0 rgB</i>	T /Overloc	:k 10 ₁ Tf 50 70
57	Preface. Infectious Disorders - Drug Targets, 2019, 19, 1-1.	0.4	5
58	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–4. Molecules, 2019, 24, 130.	1.7	4
59	Membraneâ€active peptide <scp>PV</scp> 3 efficiently eradicates multidrugâ€resistant <i>Pseudomonas aeruginosa</i> i> in a mouse model of burn infection. Apmis, 2018, 126, 114-122.	0.9	20
60	Vipers of the Middle East: A Rich Source of Bioactive Molecules. Molecules, 2018, 23, 2721.	1.7	11
61	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules, 2018, 23, 1596.	1.7	1
62	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–2. Molecules, 2018, 23, 65.	1.7	2
63	The aqueous buds extract of Eucalyptus neutralizes the main enzymatic activities of Montivipera bornmuelleri venom. Toxicon, 2018, 149, 90.	0.8	O
64	Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug resistant bacteria. Amino Acids, 2018, 50, 1231-1243.	1,2	36
65	Consequences of Androctonus mauretanicus and Buthus occitanus scorpion venoms on electrolyte levels in rabbits. Heliyon, 2017, 3, e00221.	1.4	9
66	Treating autoimmune disorders with venom-derived peptides. Expert Opinion on Biological Therapy, 2017, 17, 1065-1075.	1.4	40
67	Peptide screen identifies a new NADPH oxidase inhibitor: impact on cell migration and invasion. European Journal of Pharmacology, 2017, 794, 162-172.	1.7	11
68	Special Issue "Structure–Activity Relationship of Natural Products― Molecules, 2017, 22, 697.	1.7	O
69	CharacteristicsâandâLethalityâofâaâNovelâRecombinantâ DermonecroticâVenomâPhospholipaseâDâfromâ Hemiscorpiusâlepturus. Toxins, 2017, 9, 102.	1.5	14
70	Editorial. Infectious Disorders - Drug Targets, 2016, 16, 78-78.	0.4	O
71	Mechanism of action and inÂvitro activity of short hybrid antimicrobial peptide PV3 against Pseudomonas aeruginosa. Biochemical and Biophysical Research Communications, 2016, 479, 103-108.	1.0	25
72	Genetic Characterization of Lactic Acid Bacteria Isolated from Tunisian Milk Waste and their Antimicrobial Activity Against some Bacteria Implicated in Nosocomial Infections. Infectious Disorders - Drug Targets, 2016, 16, 182-191.	0.4	4

#	Article	IF	CITATIONS
73	Bacteriocins Active Against Multi-Resistant Gram Negative Bacteria Implicated in Nosocomial Infections. Infectious Disorders - Drug Targets, 2015, 15, 2-12.	0.4	31
74	Chlorotoxin: A Helpful Natural Scorpion Peptide to Diagnose Glioma and Fight Tumor Invasion. Toxins, 2015, 7, 1079-1101.	1.5	136
75	Comparison of the neurotoxic and myotoxic effects of two Moroccan scorpion venoms and their neutralization by experimental polyclonal antivenom. Life Sciences, 2015, 124, 1-7.	2.0	7
76	Correspondences between the binding characteristics of a non-natural peptide, Lei-Dab7, and the distribution of SK subunits in the rat central nervous system. European Journal of Pharmacology, 2015, 752, 106-111.	1.7	4
77	Endogenous animal toxin-like human \hat{l}^2 -defensin 2 inhibits own K+ channels through interaction with channel extracellular pore region. Cellular and Molecular Life Sciences, 2015, 72, 845-853.	2.4	34
78	Small-Conductance Ca2+-Activated Potassium Type 2 Channels Regulate the Formation of Contextual Fear Memory. PLoS ONE, 2015, 10, e0127264.	1.1	8
79	Protein Content Analysis and Antimicrobial Activity of the Crude Venom of Montivipera bornmuelleri; a Viper from Lebanon. Infectious Disorders - Drug Targets, 2014, 14, 49-55.	0.4	15
80	Evaluation of the Lethal Potency of Scorpion and Snake Venoms and Comparison between Intraperitoneal and Intravenous Injection Routes. Toxins, 2014, 6, 1873-1881.	1.5	26
81	Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues. Biochemical and Biophysical Research Communications, 2014, 447, 70-76.	1.0	32
82	SKCa Channels Blockage Increases the Expression of Adenosine A2AReceptor in Jurkat Human T Cells. BioResearch Open Access, 2013, 2, 163-168.	2.6	0
83	Cell Penetration Properties of a Highly Efficient Mini Maurocalcine Peptide. Pharmaceuticals, 2013, 6, 320-339.	1.7	18
84	The Deciphered Genome of Mesobuthus martensii Uncovers the Resistance Mysteries of Scorpion to Its Own Venom and Toxins at the Ion Channel Level. Toxins, 2013, 5, 2209-2211.	1.5	4
85	Two Conserved Arginine Residues from the SK3 Potassium Channel Outer Vestibule Control Selectivity of Recognition by Scorpion Toxins. Journal of Biological Chemistry, 2013, 288, 12544-12553.	1.6	26
86	Animal Toxins. , 2013, , 407-415.		3
87	Selective Positive Modulator of Calcium-Activated Potassium Channels Exerts Beneficial Effects in a Mouse Model of Spinocerebellar Ataxia Type 2. Chemistry and Biology, 2012, 19, 1340-1353.	6.2	126
88	Small Efficient Cell-penetrating Peptides Derived from Scorpion Toxin Maurocalcine. Journal of Biological Chemistry, 2012, 287, 17331-17342.	1.6	23
89	Analysis of the interacting surface of maurotoxin with the voltageâ€gated <i>Shaker</i> B K ⁺ channel. Journal of Peptide Science, 2011, 17, 200-210.	0.8	1
90	Substance P receptor blockade decreases stretchâ€induced lung cytokines and lung injury in rats. Journal of Physiology, 2010, 588, 1309-1319.	1.3	10

#	Article	IF	Citations
91	Therapeutic Value of Peptides from Animal Venoms. , 2010, , 287-303.		10
92	Proteinâ^'Protein Recognition Control by Modulating Electrostatic Interactions. Journal of Proteome Research, 2010, 9, 3118-3125.	1.8	32
93	Chemical Synthesis and Characterization of J46 Peptide, an Atypical Class IIa Bacteriocin from Lactococcus lactis subsp. cremoris J46 Strain. Journal of Antibiotics, 2008, 61, 89-93.	1.0	8
94	Effect of Cu2+on the Oxidative Folding of Synthetic MaurotoxinIn Vitro. Journal of Biomolecular Structure and Dynamics, 2008, 26, 75-81.	2.0	2
95	Design of a Disulfide-less, Pharmacologically Inert, and Chemically Competent Analog of Maurocalcine for the Efficient Transport of Impermeant Compounds into Cells. Journal of Biological Chemistry, 2008, 283, 27048-27056.	1.6	28
96	Animal Toxins Acting on Voltage-Gated Potassium Channels. Current Pharmaceutical Design, 2008, 14, 2503-2518.	0.9	128
97	Modulators of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels and their Therapeutic Indications. Current Medicinal Chemistry, 2007, 14, 1437-1457.	1.2	189
98	Chemical synthesis and 1H-NMR 3D structure determination of AgTx2-MTX chimera, a new potential blocker for Kv1.2 channel, derived from MTX and AgTx2 scorpion toxins. Protein Science, 2007, 17, 107-118.	3.1	9
99	Transient Loss of Voltage Control of Ca2+ Release in the Presence of Maurocalcine in Skeletal Muscle. Biophysical Journal, 2006, 91, 2206-2215.	0.2	26
100	Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 308-319.	1.4	53
101	CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behavioural Brain Research, 2006, 166, 230-235.	1.2	42
102	Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy. Annals of Neurology, 2006, 60, 586-596.	2.8	29
103	Pharmacological Profiling of Orthochirus scrobiculosus Toxin 1 Analogs with a Trimmed N-Terminal Domain. Molecular Pharmacology, 2006, 69, 354-362.	1.0	38
104	Structure-Function Strategies to Improve the Pharmacological Value of Animal Toxins. , 2006, , 415-419.		3
105	Differential effects of maurocalcine on Ca2+release events and depolarization-induced Ca2+release in rat skeletal muscle. Journal of Physiology, 2005, 565, 843-853.	1.3	26
106	Increasing the molecular contacts between maurotoxin and Kv1.2 channel augments ligand affinity. Proteins: Structure, Function and Bioinformatics, 2005, 60, 401-411.	1.5	10
107	The impact of the fourth disulfide bridge in scorpion toxins of the α-KTx6 subfamily. Proteins: Structure, Function and Bioinformatics, 2005, 61, 1010-1023.	1.5	21
108	Contribution of the functional dyad of animal toxins acting on voltage-gated Kv1-type channels. Journal of Peptide Science, 2005, 11, 65-68.	0.8	49

#	Article	IF	CITATIONS
109	Transduction of the Scorpion Toxin Maurocalcine into Cells. Journal of Biological Chemistry, 2005, 280, 12833-12839.	1.6	62
110	Maurocalcine and Domain A of the II-III Loop of the Dihydropyridine Receptor Cav 1.1 Subunit Share Common Binding Sites on the Skeletal Ryanodine Receptor. Journal of Biological Chemistry, 2005, 280, 4013-4016.	1.6	39
111	K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. Biochemical Journal, 2005, 385, 95-104.	1.7	103
112	Blockade of NMDA receptors enhances spontaneous sharp waves in rat hippocampal slices. Neuroscience Letters, 2005, 385, 46-51.	1.0	29
113	Molecular modeling and docking simulations of scorpion toxins and related analogs on human SKCa2 and SKCa3 channels. Peptides, 2005, 26, 1095-1108.	1.2	17
114	Evidence for Domain-specific Recognition of SK and Kv Channels by MTX and HsTx1 Scorpion Toxins. Journal of Biological Chemistry, 2004, 279, 55690-55696.	1.6	51
115	Mapping of Maurotoxin Binding Sites on hKv1.2, hKv1.3, and hIKCa1 Channels. Molecular Pharmacology, 2004, 66, 1103-1112.	1.0	48
116	First chemical synthesis of a scorpion \hat{l}_{\pm} -toxin affecting sodium channels: The Aah I toxin of Androctonus australis hector. Journal of Peptide Science, 2004, 10, 666-677.	0.8	12
117	Diversity of folds in animal toxins acting on ion channels. Biochemical Journal, 2004, 378, 717-726.	1.7	226
118	Block of maurotoxin and charybdotoxin on human intermediate-conductance calcium-activated potassium channels (hIKCa1). Toxicon, 2004, 43, 973-980.	0.8	9
119	Toxin determinants required for interaction with voltage-gated K+ channels. Toxicon, 2004, 43, 909-914.	0.8	51
120	The functional dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. Biochemical Journal, 2004, 377, 25-36.	1.7	74
121	Cobatoxin 1 from Centruroides noxius scorpion venom: chemical synthesis, three-dimensional structure in solution, pharmacology and docking on K+ channels. Biochemical Journal, 2004, 377, 37-49.	1.7	53
122	Synthesis and characterization of Pi4, a scorpion toxin from Pandinus imperator that acts on K+ channels. FEBS Journal, 2003, 270, 3583-3592.	0.2	41
123	Solution structure of Pi4, a short four-disulfide-bridged scorpion toxin specific of potassium channels. Protein Science, 2003, 12, 1844-1854.	3.1	13
124	Critical Amino Acid Residues Determine the Binding Affinity and the Ca2+ Release Efficacy of Maurocalcine in Skeletal Muscle Cells. Journal of Biological Chemistry, 2003, 278, 37822-37831.	1.6	43
125	A Maurotoxin with Constrained Standard Disulfide Bridging. Journal of Biological Chemistry, 2003, 278, 31095-31104.	1.6	22
126	Maurocalcine and Peptide A Stabilize Distinct Subconductance States of Ryanodine Receptor Type 1, Revealing a Proportional Gating Mechanism. Journal of Biological Chemistry, 2003, 278, 16095-16106.	1.6	34

#	Article	IF	Citations
127	The Interaction between the I-II Loop and the III-IV Loop of Cav2.1 Contributes to Voltage-dependent Inactivation in a \hat{l}^2 -Dependent Manner. Journal of Biological Chemistry, 2002, 277, 10003-10013.	1.6	40
128	Evolution of maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro. Biochemical Journal, 2002, 361, 409.	1.7	2
129	Evolution of maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro. Biochemical Journal, 2002, 361, 409-416.	1.7	12
130	Synthesis, 3-D Structure, and Pharmacology of a Reticulated Chimeric Peptide Derived from Maurotoxin and Tsk Scorpion Toxins. Biochemical and Biophysical Research Communications, 2002, 291, 640-648.	1.0	4
131	Modelling of the III-IV loop, a domain involved in calcium channel Cav2.1 inactivation, highlights a structural homology with the \hat{I}^3 subunit of G proteins. European Journal of Neuroscience, 2002, 16, 219-228.	1.2	9
132	A multiple branch peptide construction derived from a conserved sequence of the envelope glycoprotein gp41 inhibits human immunodeficiency virus infection., 2002,, 781-782.		0
133	Chemical Synthesis, Molecular Modeling, and Antimicrobial Activity of a Novel Bacteriocin, MMFII. Biochemical and Biophysical Research Communications, 2001, 289, 13-18.	1.0	8
134	Design and Characterization of a Highly Selective Peptide Inhibitor of the Small Conductance Calcium-activated K+Channel, SkCa2. Journal of Biological Chemistry, 2001, 276, 43145-43151.	1.6	106
135	Parameters affecting in vitro oxidation/folding of maurotoxin, a four-disulphide-bridged scorpion toxin. Biochemical Journal, 2001, 358, 681-692.	1.7	21
136	Parameters affecting in vitro oxidation/folding of maurotoxin, a four-disulphide-bridged scorpion toxin. Biochemical Journal, 2001, 358, 681.	1.7	14
137	Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation. Journal of Immunology, 2001, 166, 936-944.	0.4	180
138	A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel. Proteins: Structure, Function and Bioinformatics, 2000, 40, 436-442.	1.5	87
139	Chemical synthesis and characterization of Pi1, a scorpion toxin from Pandinus imperator active on K+channels. FEBS Journal, 2000, 267, 5149-5155.	0.2	33
140	Maurotoxin Versus Pi1/HsTx1 Scorpion Toxins. Journal of Biological Chemistry, 2000, 275, 39394-39402.	1.6	38
141	Synthesis, 1H NMR Structure, and Activity of a Three-disulfide-bridged Maurotoxin Analog Designed to Restore the Consensus Motif of Scorpion Toxins. Journal of Biological Chemistry, 2000, 275, 13605-13612.	1.6	34
142	Reversibility of the Ca2+ Channel $\hat{l}\pm 1\hat{a}\in \hat{l}^2$ Subunit Interaction. Biochemical and Biophysical Research Communications, 2000, 277, 729-735.	1.0	31
143	Mechanisms of Maurotoxin Action on Shaker Potassium Channels. Biophysical Journal, 2000, 79, 776-787.	0.2	26
144	SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells. Journal of Peptide Science, 1999, 4, 479-485.	0.8	1

#	Article	IF	CITATIONS
145	An Anti-HIV Peptide Construct Derived from the Cleavage Region of the Env Precursor Acts on Env Fusogenicity through the Presence of a Functional Cleavage Sequence. Virology, 1998, 247, 137-143.	1.1	10
146	Monoclonal antibodies neutralizing the toxin II from Androctonus australis hector scorpion venom: usefulness of a synthetic, non-toxic analog. FEBS Letters, 1997, 412, 456-460.	1.3	22
147	Anti-HIV Activity of Multibranched Peptide Constructs Derived either from the Cleavage Sequence or from the Transmembrane Domain (gp41) of the Human Immunodeficiency Virus Type 1 Envelope. Virology, 1996, 223, 406-408.	1.1	13
148	Chemical Synthesis and Characterization of Maurotoxin, a Short Scorpion Toxin with four Disulfide Bridges that Acts on K+ Channels. FEBS Journal, 1996, 242, 491-498.	0.2	96
149	Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsid. Journal of Medical Virology, 1993, 41, 221-229.	2.5	20